Vorsitz: D. Dobrev (Essen), B. Hornig (Basel, CH)
(V999) | Phoshodiesterase 2 maintains resting heart rate in the healthy heart but becomes markedly upregulated in diseased hearts and desensitizes against β-AR mediated inotropic effects |
C. Vettel, H. Mehel, J. Emons, K. Wittköpper, M. Dewenter, S. Lämmle, D. Seppelt, M. Riedel, S. Napiany, S. Lutz, S. T. Sossalla, P. Lechene, L. S. Maier, V. Nikolaev, W.-H. Zimmermann, T. Eschenhagen, G. Vandecasteele, R. Fischmeister, A. El-Armouche (Göttingen, Hamburg; Châtenay-Malabry, FR) | |
(V1000) | Gene Therapy with Glucose-related Protein 78 (GRP78) Targeting Doxorubicin Cardiomyopathy |
H. Tscheschner, J. Reinkober, P. Most, H. A. Katus, M. Müller, O. J. Müller, P. Raake (Heidelberg) | |
(V1001) | Myoscape (Muscle enriched Calcium-Channel associated protein), controls L-type Calcium Channel function and regulates cardiac contractility in vivo |
M. Eden, B. Meder, R. Will, M. Völkers, C. Heymes, G. Poomvanicha, K. Domes, H. A. Katus, F. Hofmann, W. Rottbauer, P. Most, N. Frey (Kiel, Heidelberg, München, Ulm; Paris, FR) | |
(V1002) | PKA phosphorylates the pentameric form of phospholamban, a crucial regulator of myocyte calcium cycling |
T. Wittmann, M. Lohse, J. Schmitt (Würzburg, Düsseldorf) | |
(V1003) | Nucleoside Diphosphate Kinase C is an Essential Regulator of G-Protein Content and cAMP Production in Cardiomyocytes |
I. Abu-Taha, N. Wolf, C. Würtz, S. Lutz, A. El-Armouche, V. Nikolaev, H.-J. Hippe, D. Dobrev, T. Wieland (Essen, Heidelberg, Göttingen, Kiel, Mannheim) | |
(V1004) | Global beta-adrenoceptor blockade versus genetic deletion of phosphatase inhibitor-1 in CaMKIIδc-induced severe heart failure |
M. Dewenter, S. Neef, C. Brammen, J. H. Brown, L. S. Maier, A. El-Armouche (Göttingen; La Jolla, US) |